Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
Syndax Pharmaceuticals (Nasdaq: SNDX) announced that CEO Michael A. Metzger will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, 2026 at 12:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq: SNDX) announced that CEO Michael A. Metzger will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, 2026 at 12:30 p.m. ET.
A live webcast and limited-time replay will be available in the company Investor section at www.syndax.com.
Details
News Market Reaction – SNDX
On Feb 5, the day this news came out, SNDX closed 1.37% below the previous close.
Data tracked by StockTitan Argus for the Feb 5 session.
Key Figures
- Summit date
- February 12, 2026
- Guggenheim Emerging Outlook: Biotech Summit fireside chat
- Fireside chat time
- 12:30 p.m. ET
- Scheduled start time for Guggenheim Summit fireside chat
Historical Context
-
Unaudited 4Q25 and 2025 revenues and cash position ahead of JP Morgan talk.
-
Multi-regional managed access program to broaden Revuforj availability outside U.S.
-
Announcement of CEO presentation at 44th Annual J.P. Morgan Healthcare Conference.
-
Revuforj named Best New Drug following two FDA approvals in acute leukemias.
-
Multiple Revuforj abstracts at ASH 2025 with high ORR, CR, and MRD negativity.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, 2026, at 12:30 p.m. ET.
A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.